cytomegalovirus cmv infections market 2027
DelveInsight's 'Cytomegalovirus (CMV) Infections - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CMV in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Cytomegalovirus (CMV) Infections from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2016-2027
Cytomegalovirus (CMV) Infections - Disease Understanding and Treatment Algorithm
The DelveInsight Cytomegalovirus (CMV) Infections market report gives the thorough understanding of the Cytomegalovirus (CMV) Infections by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Cytomegalovirus (CMV) Infections in the US, Europe, and Japan.
Cytomegalovirus (CMV) Infections Epidemiology
The Cytomegalovirus (CMV) Infections epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Sero Prevalence of Cytomegalovirus Infection in 7MM,Total Diagnosed CMV Patients in 7MM, Infants at High Risk of CMV, CMV Patients among Hematopoietic Stem Cell Transplants (HSCT), Number of Refractory CMV Patients after HSCT, Number of CMV Patients among Solid Organ Transplants (SOT),CMV Retinitis among HIV Patients) scenario of Cytomegalovirus (CMV) Infections in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the total sero- prevalent population of Cytomegalovirus (CMV) Infections was found to be 162,856,267 in the US in 2016.
Cytomegalovirus (CMV) Infections Drug Chapters
This segment of the Cytomegalovirus (CMV) Infections report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Currently, antiviral drugs are used to prevent CMV infection following transplant procedures. The drugs used to prevent/treat cytomegalovirus are valganciclovir, ganciclovir, cidofovir, foscarnet, or a combination etc. Ganciclovir (GCV) was the first antiviral agent approved for treatment of CMV disease, and remains the first-line treatment for CMV infection and CMV disease in transplant recipients. Valganciclovir (Valcyte) which is a prodrug of ganciclovir is the best drug for prophylaxis because it is effective and available in oral form, its high cost limits its use. Valganciclovir was approved in 2000 for treatment of CMV retinitis in AIDS patients and was later approved for prophylactic treatment of CMV in certain SOT recipients.
Four upcoming therapies are expected to enter the therapeutic market of Cytomegalovirus (CMV) Infections in 7MM during the forecast period (2018-2027). Detailed chapters of upcoming therapies like Cannabinoid receptor CB1 antagonists, Epidiolex (GW Pharmaceuticals) and Enzyme cholesterol 24-hydroxylase (CH24H) Inhibitor, TAK-935 (Takeda Pharmaceutical Company Limited) have also been covered in the report.
Cytomegalovirus (CMV) Infections Market Outlook
The Cytomegalovirus (CMV) Infections market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Cytomegalovirus (CMV) Infections in 7MM was found to be USD 840.6 million in 2016.
Cytomegalovirus (CMV) Infections Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Cytomegalovirus (CMV) Infections Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Cytomegalovirus (CMV) Infections Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Cytomegalovirus (CMV) Infections Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Cytomegalovirus (CMV) Infections market
• Organize sales and marketing efforts by identifying the best opportunities for Cytomegalovirus (CMV) Infections market
• To understand the future market competition in the Cytomegalovirus (CMV) Infections market.
1. Key Insights
2. Cytomegalovirus (CMV) Infections (TSC) Market Overview at a Glance
2.1. Market Share (%) Distribution of TSC in 2017
2.2. Market Share (%) Distribution of TSC in 2027
3. Disease Overview: Cytomegalovirus (CMV) Infections (TSC)
3.1. Introduction
3.2. Clinical Manifestations of Cytomegalovirus (CMV) Infections
3.3. Etiology
3.4. Risk Factors
3.5. Inheritance Pattern
3.6. Signs and Symptoms
3.7. Pathophysiology
3.7.1. Cytomegalovirus (CMV) Infections (TSC) Genotype Analysis
3.8. Diagnosis
3.8.1. Differential Diagnosis
3.8.2. Diagnostic Criteria
3.8.3. Diagnostic Recommendations
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
5. 7MM Total Prevalent Patient Population of Cytomegalovirus (CMV) Infections
6. Country Wise-Epidemiology of Cytomegalovirus (CMV) Infections
6.1. United States
6.1.1. Prevalent Population of Cytomegalovirus (CMV) Infections in the United States
6.1.2. Familiar Prevalent Cases of Cytomegalovirus (CMV) Infections
6.1.3. De novo mutations Prevalent Cases of Cytomegalovirus (CMV) Infections
6.2. Germany
6.2.1. Prevalent Population of Cytomegalovirus (CMV) Infections in Germany
6.2.2. Familiar Prevalent Cases of Cytomegalovirus (CMV) Infections
6.2.3. De novo mutations Prevalent Cases of Cytomegalovirus (CMV) Infections
6.3. France
6.3.1. Prevalent Population of Cytomegalovirus (CMV) Infections in France
6.3.2. Familiar Prevalent Cases of Cytomegalovirus (CMV) Infections
6.3.3. De novo mutations Prevalent Cases of Cytomegalovirus (CMV) Infections
6.4. Italy
6.4.1. Prevalent Population of Cytomegalovirus (CMV) Infections in Italy
6.4.2. Familiar Prevalent Cases of Cytomegalovirus (CMV) Infections
6.4.3. De novo mutations Prevalent Cases of Cytomegalovirus (CMV) Infections
6.5. Spain
6.5.1. Prevalent Population of Cytomegalovirus (CMV) Infections in Spain
6.5.2. Familiar Prevalent Cases of Cytomegalovirus (CMV) Infections
6.5.3. De novo mutations Prevalent Cases of Cytomegalovirus (CMV) Infections
6.6. United Kingdom
6.6.1. Prevalent Population of Cytomegalovirus (CMV) Infections in the UK
6.6.2. Familiar Prevalent Cases of Cytomegalovirus (CMV) Infections
6.6.3. De novo mutations Prevalent Cases of Cytomegalovirus (CMV) Infections
6.7. Japan
6.7.1. Prevalent Population of Cytomegalovirus (CMV) Infections in Japan
6.7.2. Familiar Prevalent Cases of Cytomegalovirus (CMV) Infections
6.7.3. De novo mutations Prevalent Cases of Cytomegalovirus (CMV) Infections
7. Current Treatment Practices
7.1. Therapeutic Goals
7.2. General Treatment Practices
7.3. Treatment Algorithm
7.4. Treatment Guidelines
7.4.1. International Cytomegalovirus (CMV) Infections Consensus Conference: Cytomegalovirus (CMV) Infections Surveillance and Management: Recommendations
8. Unmet Needs
9. Marketed drugs
9.1. Comparison of Marketed Drugs
9.2. Everolimus: Novartis Pharmaceuticals
9.2.1. Product Description
9.2.2. Mechanism of Action
9.2.3. Regulatory Milestones
9.2.4. Safety and Efficacy
9.2.5. Side effects
9.2.6. Product Profile
9.3. Rapalimus: Nobelpharma Co., Ltd
9.3.1. Product Description
9.3.2. Mechanism of Action
9.3.3. Regulatory Milestones
9.3.4. Safety and Efficacy
9.3.5. Side effects
9.3.6. Product Profile
10. Emerging Therapies
10.1. Emerging Therapies: Key Cross Comparison
10.2. Epidiolex: GW Pharmaceuticals
10.2.1. Drug Description
10.2.2. Regulatory Milestones
10.2.3. Other Development Activities
10.2.4. Clinical Development
10.2.5. Clinical Trials Information
10.2.6. Product Profile
10.3. TAK-935: Takeda Pharmaceutical Company Limited
10.3.1. Drug Description
10.3.2. Other Development Activities
10.3.3. Clinical Development
10.3.4. Clinical Trials Information
10.3.5. Product Profile
11. Cytomegalovirus (CMV) Infections: 7 Major Market Analysis
11.1. Key Findings
11.2. Market Size of Cytomegalovirus (CMV) Infections in 7MM
12. Market Outlook by Country
13. The United States: Market Outlook
13.1. United States Market Size
13.1.1. Total Market size of Cytomegalovirus (CMV) Infections
13.1.2. Cytomegalovirus (CMV) Infections Market by Therapies
14. EU-5 Countries: Market Outlook
14.1. Germany
14.1.1. Total Market size of Cytomegalovirus (CMV) Infections
14.1.2. Cytomegalovirus (CMV) Infections Market by Therapies
14.2. France
14.2.1. Total Market size of Cytomegalovirus (CMV) Infections
14.2.2. Cytomegalovirus (CMV) Infections Market by Therapies
14.3. United Kingdom
14.3.1. Total Market size of Cytomegalovirus (CMV) Infections
14.3.2. Cytomegalovirus (CMV) Infections Market by Therapies
14.4. Spain
14.4.1. Total Market size of Cytomegalovirus (CMV) Infections
14.4.2. Cytomegalovirus (CMV) Infections Market by Therapies
14.5. Italy
14.5.1. Total Market size of Cytomegalovirus (CMV) Infections
14.5.2. Cytomegalovirus (CMV) Infections Market by Therapies
14.6. Japan: Market Outlook
14.6.1. Total Market size of Cytomegalovirus (CMV) Infections
14.6.2. Cytomegalovirus (CMV) Infections Market by Therapies
15. Market Drivers
16. Market Barriers
17. Appendix
17.1. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
List of Tables:
Table 1: Total Sero-Prevalence of Cytomegalovirus Infection in 7MM (2016-2027)
Table 2: Total Diagnosed CMV Patients in 7MM (2016-2027)
Table 3: Total CMV Patients in the US (2016-2027)
Table 4: Infants at High Risk of CMV in the US (2016-2027)
Table 5: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the US (2016-2027)
Table 6: Number of Refractory CMV Patients after HSCT in the US (2016-2027)
Table 7: Number of CMV Patients among SOT in the US (2016-2027)
Table 8: CMV Retinitis among HIV Patients in the US (2016-2027)
Table 9: Total CMV Patients in Germany (2016-2027)
Table 10: Number of Infants born with Congenital CMV in Germany (2016-2027)
Table 11: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Germany (2016-2027)
Table 12: Number of Refractory CMV Patients after HSCT in Germany (2016-2027)
Table 13: Number of CMV Patients among SOT in Germany (2016-2027)
Table 14: Total CMV Patients in France (2016-2027)
Table 15: Number of Infants born with Congenital CMV in France (2016-2027)
Table 16: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in France (2016-2027)
Table 17: Number of Refractory CMV Patients after HSCT in France (2016-2027)
Table 18: Number of CMV Patients among SOT in France (2016-2027)
Table 19: CMV Retinitis among HIV Patients in France (2016-2027)
Table 20: Total CMV Patients in Italy (2016-2027)
Table 21: Number of Infants born with Congenital CMV in Italy (2016-2027)
Table 22: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Italy (2016-2027)
Table 23: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Italy (2016-2027)
Table 24: Number of CMV Patients among SOT in Italy (2016-2027)
Table 25: CMV Retinitis among HIV Patients in Italy (2016-2027)
Table 26: Total CMV Patients in Spain (2016-2027)
Table 27: Number of Infants born with Congenital CMV in Spain 2016-2027)
Table 28: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Spain (2016-2027)
Table 29: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Spain (2016-2027)
Table 30: Number of CMV Patients among SOT in Spain (2016-2027)
Table 31: HIV Patients at High Risk of CMV in Spain (2016-2027)
Table 32: Total CMV Patients in the UK (2016-2027)
Table 33: Number of Infants born with Congenital CMV in the UK (2016-2027)
Table 34: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the UK (2016-2027)
Table 35 Number of Refractory CMV Patients after HSCT in the UK (2016-2027)
Table 36: Number of CMV Patients among SOT in the UK (2016-2027)
Table 37: CMV Retinitis among HIV Patients in the UK (2016-2027)
Table 38: Total CMV Patients in Japan (2016-2027)
Table 39: Number of Infants born with Congenital CMV in Japan (2016-2027)
Table 40: CMV Patients among HSCT Patients in Japan (2016-2027)
Table 41: Number of Refractory CMV Patients after HSCT in Japan (2016-2027)
Table 42: Number of CMV Patients among SOT in Japan (2016-2027)
Table 43: CMV Retinitis among HIV Patients in Japan (2016-2027)
Table 44: Phase II/III drug analysis
Table 45: Cytotect CP70, Clinical Trial Description, 2018
Table 46: Maribavir, Clinical Trial Description, 2018
Table 47: CMV-pp65 CTLs, Clinical Trial Description, 2018
Table 48: Triplex, Clinical Trial Description, 2018
Table 49: CSJ148, Clinical Trial Description, 2018
Table 50: Viralym-M, Clinical Trial Description, 2018
Table 51: Viralym-M, Clinical Trial Description, 2018
Table 52: ASP0113, Clinical Trial Description, 2018
Table 53: 7 Major Market Size of Cytomegalovirus Infection in USD Million (2016-2027)
Table 54: 7 Major Market Size of Prophylactic CMV Infection in USD Million (2016-2027)
Table 55: 7 Major Market Size of Therapeutic CMV Infection in USD Million (2016-2027)
Table 56: Market Size of Cytomegalovirus Infection in the United States, in USD Million (2016-2027)
Table 57:Market size of Prophylaxis CMV by therapies in the United States, in USD Million (2016-2027)
Table 58:Market size of Therapeutic CMV by therapies in the United States, in USD Million (2016-2027)
Table 59: Market Size of Cytomegalovirus Infection in Germany, in USD Million (2016-2027)
Table 60:Market size of Prophylaxis CMV by therapies in Germany, in USD Million (2016-2027)
Table 61:Market size of Therapeutic CMV by therapies in Germany, in USD Million (2016-2027)
Table 62: Market Size of Cytomegalovirus Infection in France, in USD Million (2016-2027)
Table 63:Market size of Prophylaxis CMV by therapies in France, in USD Million (2016-2027)
Table 64:Market size of Therapeutic CMV by therapies in France, in USD Million (2016-2027)
Table 65: Market Size of Cytomegalovirus Infection in Italy, in USD Million (2016-2027)
Table 66:Market size of Prophylaxis CMV by therapies in Italy, in USD Million (2016-2027)
Table 67:Market size of Therapeutic CMV by therapies in Italy, in USD Million (2016-2027)
Table 68: Market Size of Cytomegalovirus Infection in Spain, in USD Million (2016-2027)
Table 69:Market size of Prophylaxis CMV by therapies in Spain, in USD Million (2016-2027)
Table 70:Market size of Therapeutic CMV by therapies in Spain, in USD Million (2016-2027)
Table 71: Market Size of Cytomegalovirus Infection in the UK, in USD Million (2016-2027)
Table 72:Market size of Prophylaxis CMV by therapies in the UK, in USD Million (2016-2027)
Table 73:Market size of Therapeutic CMV by therapies in the UK, in USD Million (2016-2027)
Table 74: Market Size of Cytomegalovirus Infection in Japan, in USD Million (2016-2027)
Table 75:Market size of Prophylaxis CMV by therapies in Japan, in USD Million (2016-2027)
Table 76:Market size of Therapeutic CMV by therapies in Japan, in USD Million (2016-2027)
List of Figures:
Figure 1: Classification of CMV
Figure 2: Risk Factors CMV infection
Figure 3: Mechanisms used by Human cytomegalovirus to interfere with cell-mediated immunity
Figure 4: Impact of the immune system on CMV
Figure 5: CMV Disease Mechanisms
Figure 6: Total Sero Prevalence of Cytomegalovirus Infection in 7MM (2016-2027)
Figure 7: Total Diagnosed CMV Patients in 7MM (2016-2027)
Figure 8: Total CMV Patients in the US (2016-2027)
Figure 9: Infants at High Risk of CMV in the US (2016-2027)
Figure 10: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the US (2016-2027)
Figure 11: Number of Refractory CMV Patients after HSCT in the US (2016-2027)
Figure 12: Number of CMV Patients among SOT in the US (2016-2027)
Figure 13: CMV Retinitis among HIV Patients in the US (2016-2027)
Figure 14: Total CMV Patients in Germany (2016-2027)
Figure 15: Number of Infants born with Congenital CMV in Germany (2016-2027)
Figure 16: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Germany (2016-2027)
Figure 17: Number of Refractory CMV Patients after HSCT in Germany (2016-2027)
Figure 18: Number of CMV Patients among SOT in Germany (2016-2027)
Figure 19: CMV Retinitis among HIV Patients in Germany (2016-2027)
Figure 20: CMV Retinitis among HIV Patients in Germany (2016-2027)
Figure 21: Total CMV Patients in France (2016-2027)
Figure 22: Number of Infants born with Congenital CMV in France (2016-2027)
Figure 23: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in France (2016-2027)
Figure 24:Number of Refractory CMV Patients after HSCT in France (2016-2027)
Figure 25: Number of CMV Patients among SOT in France (2016-2027)
Figure 26: CMV Retinitis among HIV Patients in France (2016-2027)
Figure 27: Total CMV Patients in Italy (2016-2027)
Figure 28: Number of Infants born with Congenital CMV in Italy (2016-2027)
Figure 29: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Italy (2016-2027)
Figure 30: Number of Refractory CMV Patients after HSCT in Italy (2016-2027)
Figure 31: Number of CMV Patients among SOT in Italy (2016-2027)
Figure 32: CMV Retinitis among HIV Patients in Italy (2016-2027)
Figure 33: Total CMV Patients in Spain (2016-2027)
Figure 34: Number of Infants born with Congenital CMV in Spain (2016-2027)
Figure 35: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Spain (2016-2027)
Figure 36: Number of Refractory CMV Patients after HSCT in Spain (2016-2027)
Figure 37: Number of CMV Patients among SOT in Spain (2016-2027)
Figure 38: HIV Patients at High Risk of CMV in Spain (2016-2027)
Figure 39: Total CMV Patients in the UK (2016-2027)
Figure 40: Number of Infants born with Congenital CMV in the UK (2016-2027)
Figure 41: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the UK (2016-2027)
Figure 42: Number of Refractory CMV Patients after HSCT in the UK (2016-2027)
Figure 43: Number of CMV Patients among SOT in the UK (2016-2027)
Figure 44: CMV Retinitis among HIV Patients in the UK (2016-2027)
Figure 45: Total CMV Patients in Japan (2016-2027)
Figure 46: Number of Infants born with Congenital CMV in Japan (2016-2027)
Figure 47: CMV Patients among HSCT in Japan (2016-2027)
Figure 48: Number of Refractory CMV Patients after HSCT in Japan (2016-2027)
Figure 49: Number of CMV Patients among SOT in Japan (2016-2027)
Figure 50: CMV Retinitis among HIV Patients in Japan (2016-2027)
Figure 51: Treatment of CMV Infections
Figure 52: Algorithm for treatment of Ganciclovir Resistance
Figure 53: Proposed algorithm for management of suspected antiviral drug resistance
Figure 54: Unmet Needs of CMV Infections
Figure 55: 7 Major Market Size of Cytomegalovirus Infection in USD Million (2016-2027)
Figure 56: 7 Major Market Size of Prophylactic CMV Infection in USD Million (2016-2027)
Figure 57: 7 Major Market Size of Therapeutic CMV Infection in USD Million (2016-2027)
Figure 58: Market Size of Cytomegalovirus Infection in the US, USD Millions (2016-2027)
Figure 59: Market size of Prophylaxis CMV by therapies in the US, in USD Million (2016-2027)
Figure 60: Market size of Therapeutic CMV by therapies in the US, in USD Million (2016-2027)
Figure 61: Market Size of Cytomegalovirus Infection in the Germany, USD Millions (2016-2027)
Figure 62: Market size of Prophylaxis CMV by therapies in Germany, in USD Million (2016-2027)
Figure 63: Market size of Therapeutic CMV by therapies in Germany, in USD Million (2016-2027)
Figure 64: Market Size of Cytomegalovirus Infection in France, USD Millions (2016-2027)
Figure 65: Market size of Prophylaxis CMV by therapies in France, in USD Million (2016-2027)
Figure 66: Market size of Therapeutic CMV by therapies in France, in USD Million (2016-2027)
Figure 67: Market Size of Cytomegalovirus Infection in Italy, USD Millions (2016-2027)
Figure 68: Market size of Prophylaxis CMV by therapies in Italy in USD Million (2016-2027)
Figure 69: Market size of Therapeutic CMV by therapies in Italy in USD Million (2016-2027)
Figure 70: Market Size of Cytomegalovirus Infection in Spain, USD Millions (2016-2027)
Figure 71: Market size of Prophylaxis CMV by therapies in Spain, in USD Million (2016-2027)
Figure 72: Market size of Therapeutic CMV by therapies in Spain, in USD Million (2016-2027)
Figure 73: Market Size of Cytomegalovirus Infection in the UK, USD Millions (2016-2027)
Figure 74: Market size of Prophylaxis CMV by therapies in the UK, in USD Million (2016-2027)
Figure 75: Market size of Therapeutic CMV by therapies in the UK, in USD Million (2016-2027)
Figure 76: Market Size of Cytomegalovirus Infection in Japan, USD Millions (2016-2027)
Figure 77: Market size of Prophylaxis CMV by therapies in Japan, in USD Million (2016-2027)
Figure 78: Market size of Therapeutic CMV by therapies in Japan, in USD Million (2016-2027)
Figure 79: Market Drivers
Figure 80:Market Barriers
